Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC–TRIM registry
British Journal of Dermatology · 2026-10-10
DOI: 10.1093/bjd/ljag445 ↗Abstract
This study observed the real-world outcomes with avelumab treatment in patients with Merkel cell carcinoma (MCC) in Germany by immunocompromised status. Objective response rates with avelumab as first-line treatment were similar in immunocompromised and immunocompetent patients; however, long-term survival was shorter in the immunocompromised subgroup. Rates of avelumab-related adverse drug reactions were comparable between the subgroups. These findings demonstrate the clinical activity and safety of avelumab in both immunocompetent and immunocompromised patients with MCC.
EUVIMED